These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9367793)

  • 21. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
    Akhtar S; Rossi JJ
    J Antimicrob Chemother; 1996 Aug; 38(2):159-65. PubMed ID: 8877530
    [No Abstract]   [Full Text] [Related]  

  • 22. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.
    von Weizsäcker F; Wieland S; Köck J; Offensperger WB; Offensperger S; Moradpour D; Blum HE
    Hepatology; 1997 Aug; 26(2):251-5. PubMed ID: 9252130
    [No Abstract]   [Full Text] [Related]  

  • 23. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance.
    Funato T
    Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319
    [No Abstract]   [Full Text] [Related]  

  • 24. Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?
    Kronenwett R; Haas R
    Recent Results Cancer Res; 1998; 144():127-38. PubMed ID: 9304714
    [No Abstract]   [Full Text] [Related]  

  • 25. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oligomeric nucleic acids as antivirals.
    Mescalchin A; Restle T
    Molecules; 2011 Jan; 16(2):1271-96. PubMed ID: 21278679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a nonviral vector to express a chimeric tRNA-ribozyme against lymphocytic choriomeningitis virus: cytoplasmic accumulation of a catalytically competent transcript but minimal antiviral effect.
    Gebhard JR; Perry CM; Mahadeviah S; Whitton JL
    Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):3-11. PubMed ID: 9055033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
    Uhlmann E
    Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A good antisense molecule is hard to find.
    Branch AD
    Trends Biochem Sci; 1998 Feb; 23(2):45-50. PubMed ID: 9538686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligonucleotide therapeutics.
    Cohen JS
    Trends Biotechnol; 1992 Mar; 10(3):87-91. PubMed ID: 1371926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The versatility of oligonucleotides as potential therapeutics.
    Eckstein F
    Expert Opin Biol Ther; 2007 Jul; 7(7):1021-34. PubMed ID: 17665991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of bacterial RNase P RNA as a drug target.
    Willkomm DK; Gruegelsiepe H; Goudinakis O; Kretschmer-Kazemi Far R; Bald R; Erdmann VA; Hartmann RK
    Chembiochem; 2003 Oct; 4(10):1041-8. PubMed ID: 14523922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease.
    Moore SM; Skowronska-Krawczyk D; Chao DL
    Adv Exp Med Biol; 2019; 1185():85-89. PubMed ID: 31884593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Making sense of antisense.
    Murakami A
    Trends Mol Med; 2001 Oct; 7(10):430-1. PubMed ID: 11597507
    [No Abstract]   [Full Text] [Related]  

  • 40. Towards genomic drug therapy with antisense oligonucleotides.
    Lönnberg H; Vuorio E
    Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.